Abstract: Background: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the -galac-tosidase A (GLA) gene causing deficiency of -galactosidase A which results in progressive glycosphingolipid ac-cumulation, especially globotriaosylceramide (Gb3), in body liquids and lysosomes. In a large cohort of FD patients, we aimed to establish genotype/phenotype relations as indicated by serum LysoGb3 (deacylated Gb3). Methods: In 69 consecutive adult FD patients (males: n =28(41%)) witha GLA-mutation confirmed diagnosis, we conducted a multidisciplinary clinical characterization during their routine annual examinations, and mea-sured serum LysoGb3 levels by high-sensitive electrospray ionization liquid chromatography tandem mass spec-trometry. Results: Serum levels of LysoGb3 were significantly higher in Classic compared with Later-Onset phenotype and higher in the latter compared with controls, both in males (52 [40-83] Multivar-iate linear regression analysis showed that LysoGb3 levels were independently associated with, serum creatinine ( = 0.09, 95%CI 0.04-0.13, P b 0.001) and the presence of cardiomyopathy ( = 25, 95%CI 9.8-41, P =0.002). LysoGb3 levels were higher in males with frame-shift and nonsense mutations than in males with missense mu-tations (84 [72-109] vs 41 [37-52] ng/ml, P = 0.002). Conclusion: LysoGb3 relates to disease severity, enzyme replacement response, and to the genotype severity in males. LysoGb3 supports identifying patients at risk who require intensive monitoring and treatment. LysoGb3 appears to be one marker of metabolic phenotyping of FD. 
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Fabry disease (FD) (OMIM#301500) is an X-linked disease, resulting from the 68 deficient activity of the lysosomal enzyme α-galactosidase A (α-Gal A) [ lower than in FD patients ( Figure 1A and 1B). LysoGb3 levels were higher in group A than in group B (Figure 3 ). In contrast, in 
